###### Strengths and limitations

-   We assessed data from both randomised trials and observational studies.

-   The risk of bias across most observational studies is high, which raises concerns in pooling data with the far smaller randomised trials.

-   To reduce the impact of the potential bias, before meta-analysis we adjusted the within-study variance--covariance matrix of observational studies at a critical risk of bias using a precision correction, a weight factor that provides more conservative pooled estimates.

-   Key data were not adequately reported across many of the included studies.

-   We used the Grading of Recommendations Assessment, Development and Evaluation approach to appraise the available evidence.

Introduction {#s1}
============

Worldwide, cardiovascular events are the leading cause of death.[@R1] The burden of disease will likely remain high[@R2] as the incidence of cardiovascular events is expected to continue increasing.[@R4]

Antiplatelet agents (aspirin and P2Y12 inhibitors), anticoagulants and coronary revascularisation are the mainstay in the early treatment of acute coronary syndrome (ACS), and their use likely improves prognosis.[@R5] In both Europe and the USA, morphine, a potent analgesic that is a competitive agonist of μ-receptors in the central nervous system and smooth muscle, is recommended for pain control in the ACS setting.[@R7] However, the activation of opioid receptors in the myenteric plexus decreases gut motility and secretion, inhibiting the activation of P2Y12 inhibitors by decreasing their absorption and bioavailability.[@R8] There is conflict regarding the possibility that morphine interferes with P2Y12 inhibitors in the achievement of an adequate antithrombotic milieu,[@R7] which may decrease the efficaciousness of antiplatelet drugs, if these are given concurrently with morphine. We conducted a systematic review of randomised-controlled trials (RCTs) and observational studies to evaluate the safety of morphine use in ACS, hypothesising that we would find a clinically meaningful result.

Methods {#s2}
=======

This systematic review followed the reporting principles of Meta-analysis Of Observational Studies in Epidemiology and Preferred Reporting Items for Systematic Reviews and Meta-Analyses.[@R11]Patients and public were not involved in this review.

Eligibility criteria {#s2a}
--------------------

We considered longitudinal studies (ie, RCTs and observational studies) evaluating the impact of morphine in cardiovascular outcomes or platelet reactivity measures. The target population was patients with ACS, which can be either ST-elevated myocardial infarction (STEMI) or non-ST elevated acute coronary syndrome (NSTE-ACS).[@R13] Studies had to evaluate morphine (irrespective of the administration route or dose) against placebo, control (no intervention arm) or any other analgesic non-opioid drug.

Primary outcomes were in-hospital mortality and major adverse cardiovascular events (MACE), as defined by the PLATO trial (cardiovascular mortality, non-fatal MI or non-fatal stroke).[@R14] Secondary outcomes comprised additional safety outcomes, as defined within the included studies (as reported in the original studies, including morphine-related adverse events such as bleeding, nausea/emesis, bradycardia, hypotension and respiratory insufficiency) and platelet reactivity (a pharmacodynamic outcome, sought through the VerifyNow method, which is the most widely used assay to evaluate platelet reactivity and shows a stronger correlation with MACE in ACS than other methods, namely multiple electrode aggregometry (MEA)/Multiplate[@R10]). VerifyNow is a blood test that measures platelet reactivity by the rate and extent of light changes in whole blood as platelets aggregate, and therefore measures platelet response to major antiplatelet agents.[@R16]

Information sources and search method {#s2b}
-------------------------------------

Potentially eligible studies were identified through an electronic search of CENTRAL (Cochrane Library), MEDLINE, EMBASE, and clinicaltrials.gov from inception to November 2018 (online [supplementary material](#SP1){ref-type="supplementary-material"}). No language restrictions were applied. We cross-checked reference lists of reports for potential additional studies.

10.1136/bmjopen-2018-025232.supp1

Study selection and data collection process {#s2c}
-------------------------------------------

Two reviewers (GSD and either FBR or ANF) independently screened the titles and abstracts yielded by the search and assessed the full texts of the selected studies to determine the appropriateness for inclusion. Disagreements were resolved through consensus or by a third reviewer (DC) serving as final arbitrator. The reasons for exclusion were recorded at the full-text screening stage.

Two reviewers (ANF and GSD) extracted study data following a pre-established data collection form. Data from studies' plots were retrieved through Plot Digitizer V.2.6.8. When studies presented different estimates of the outcome of interest, we extracted the most precise or adjusted measures.

Risk of bias was independently evaluated by two authors (GSD and ANF) using different tools according to study design. For RCTs, we used the Cochrane risk of bias tool, where domains were qualitatively classified as at high, unclear or low risk of bias.[@R17] The overall risk of bias for each RCT was divided as high or low risk, with high risk being those RCTs in which at least one domain was assessed at a high risk of bias, or more than three domains were had a rating of unclear. For observational studies we used the ROBINS-I tool, assessing the following domains: confounding, selection of participants, classification of intervention, deviations from intervention, missing data, measurement of outcome and selection of reported results.[@R18] These domains were qualitatively classified as at critical, serious, moderate or low risk of bias. The overall risk of bias for each observational study was divided as critical or non-critical, following ROBINS-I criteria. Risk of bias graphs was derived from these tools.

Statistical analysis {#s2d}
--------------------

We used OpenMetaAnalyst[@R19] and Review Manager[@R20] for statistical analysis and to derive forest plots. We used a random-effects model to pool data owing to the anticipated heterogeneity in the included trials, in particular differences in study design. We reported pooled dichotomous data using risk ratios (RRs) and continuous data the mean difference (MD), reporting 95% CIs and corresponding p values for both. Heterogeneity was assessed using I.[@R2] [@R21] We present effect estimates as RR because relative estimates are more similar across studies with different designs, populations and lengths of follow-up than absolute effects.[@R22] When raw data or RR was unavailable, we used the HR or OR provided the estimate was small.[@R23] Preplanned subgroup analyses considering study design (RCTs and observational studies) and ACS type were conducted. A sensitivity analysis was also performed, in which RCTs at high risk of bias and observational studies at critical risk of bias were excluded from the analysis. Reporting bias was performed through funnel plot examination and statistical methods providing that a sufficient number of studies were included.[@R25]

When observational studies were assessed as having a critical risk of bias, we adjusted the within-study variance--covariance matrix using a precision correction of 0.1 that will provide more conservative pooled estimates.[@R26] This conservative weight factor was based on expert-based clinical grounds.

We used the Grading of Recommendations, Assessment and Evaluation (GRADE) framework to report the overall quality of evidence. The certainty in the evidence for each outcome was graded as high, moderate, low or very low.[@R28]

Patient and public involvement {#s2e}
------------------------------

Patients and the public were not involved in this review.

Results {#s3}
=======

Included studies {#s3a}
----------------

The search returned 1419 records, resulting in 1035 records after removing all duplicates. After title and abstract screening, 53 articles were assessed for full-text screening, with 17 being included for qualitative and quantitative syntheses, 5 being RCTs[@R29] and 12 being observational studies.[@R10] We did not retrieve any unpublished study ([figure 1](#F1){ref-type="fig"}).

![Study flow diagram.](bmjopen-2018-025232f01){#F1}

The characteristics of the included studies can be seen in [table 1](#T1){ref-type="table"} and [table 2](#T2){ref-type="table"}. Study publication dates ranged from 1969 to 2018, with sample sizes between 12 and 57 039 participants. The largest study, Meine *et al*,[@R34] a retrospective cohort study, accounted for 81% of the participants in this review.

###### 

Characteristics of the randomised controlled trials

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                           Location                Mean follow-up   Patients                                                                           Antiplatelet medication used   Morphine characteristics                 Comparator   N (total)   Mean age   Primary outcome
  ----------------------------------------------- ----------------------- ---------------- ---------------------------------------------------------------------------------- ------------------------------ ---------------------------------------- ------------ ----------- ---------- -------------------------------------------------------------------------------------------------------------------
  Bressan *et al*[@R31]                           Single centre, Italy    24 hours         Patients with AMI, chest pain and symptoms\<6 hour                                 None                           10 mg IM single dose                     Indoprofen   40          54         Assessment of analgesic effect of indoprofen in AMI patients

  Everts *et al*[@R29]\                           Single centre, Sweden   6 months         Patients admitted to the coronary care unit because of symptoms of suspected AMI   None                           2--7.5 mg IV, single to multiple doses   Metoprolol   265         66.6       Assessment of analgesic effect of metoprolol in suspected or definitive AMI patients
  (MEMO Study)                                                                                                                                                                                                                                                                            

  Kubica *et al*[@R30]\                           Single centre, Poland   Hospital stay    Patient with the diagnosis of STEMI or NSTEMI                                      Aspirin and ticagrelor         5 mg IV single dose                      Placebo      70          61.6       Assess the influence of morphine on pharmacokinetics and pharmacodynamics of ticagrelor and its active metabolite
  (IMPRESSION Study)                                                                                                                                                                                                                                                                      

  Lapostolle *et al*[@R32] (ATLANTIC--Morphine)   Multicentre             30 days          STEMI                                                                              Aspirin and ticagrelor         NR                                       Placebo      1862        60.8       TIMI Flow Grade 3 of culprit vessel at initial angiography and ST-segment elevation resolution Pre-PCI≥70%\
                                                                                                                                                                                                                                                                                          (coprimary outcomes)

  Thomas *et al*[@R33]                            Single centre, UK       24 hours         STEMI                                                                              Aspirin and prasugrel          5 mg IV single dose                      Placebo      12          64         VerifyNow platelet reactivity
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AMI, acute myocardial infarction; IM, intramuscular; IV, intravenous; NR, not reported; NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction.

###### 

Characteristics of the non-randomised studies

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                    Location, study design                   Follow-up (years)   Patients                                                                      Antiplatelet medication used                                       Morphine characteristics            Comparator        N        Mean age (SD)   Outcome measures                                                                                                                           Ascertainment                           Outcome adjustments for confounders   
  ---------------------------------------- ---------------------------------------- ------------------- ----------------------------------------------------------------------------- ------------------------------------------------------------------ ----------------------------------- ----------------- -------- --------------- ------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------- ------------------------------------- ------------------------------------------------------------------------------------------------
  Bellandi *et al*[@R36]                   Italy, Greece, prospective               2                   STEMI patients undergoing PPCI and receiving either prasugrel or ticagrelor   NR                                                                 6±3 mg, no additional information   No intervention   182      64 (13)         Myocardial reperfusion by early ST-segment resolution                                                                                      According to the physician's decision   Operator blinded to morphine use      NR

  Bonin *et al*[@R41]                      France, retrospective                    1                   STEMI                                                                         NR                                                                 NR                                  No intervention   969      60 (13)         MACE                                                                                                                                       According to the physician's decision   NR                                    Adjusted for baseline patient clinical risk factors

  Danchin *et al*[@R42]                    France, retrospective                    1                   STEMI                                                                         DAPT\                                                              NR                                  No intervention   3548     63 (12)         All-cause mortality                                                                                                                        According to the physician's decision   NR                                    NR
                                                                                                                                                                                      NR                                                                                                                                                                                                                                                                                                                                                                         

  Farag *et al*[@R43]                      UK, prospective single centre            30 days             STEMI                                                                         DAPT97.0% Aspirin79.0% Ticagrelor17.3% Clopidogrel0.7% Prasugrel   5--10 mg IV                         No intervention   300      64 (13)         MACE and major bleeding                                                                                                                    According to the physician's decision   NR                                    NR

  Franchi *et al*[@R45]                    USA, posthoc analysis of RCT             1                   STEMI patients undergoing PPCI                                                Aspirin and ticagrelor                                             NR                                  No intervention   46       59              Asses the pharmacokinetic and pharmacodynamics of escalating doses of ticagrelor                                                           According to the physician's decision   VerifyNow and VASP assays             Baseline\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Platelet reactivity unit values

  Grendahl\                                Norway, prospective                      NR                  Uncomplicated AMI\<48 hour of symptoms                                        NR                                                                 150 mg IV single dose               Placebo           20       NR              Assess the circulatory effects of morphine                                                                                                 NR                                      NR                                    NR
  and Hansteen[@R38]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Johnson *et al*[@R40]                    UK, posthoc analysis                     1.5                 STEMI                                                                         Aspirin and prasugrel                                              NR                                  No intervention   106      61.1 (11.7)     Platelet reactivity                                                                                                                        According to the physician's decision   Multiplate assay                      NR

  McCarthy *et al*[@R44]                   USA, retrospective                       Hospital stay       STEMI and NSTE-ACS                                                            Insufficient detail                                                NR                                  No intervention   3027     62 (12)         Mortality                                                                                                                                  According to the physician's decision   NR                                    Adjusted for baseline patient clinical risk factors and interventions used

  Meine *et al*[@R34]                      USA, retrospective                       2.5                 NSTEMI                                                                        Insufficient detail                                                IV, no additional information       No intervention   57 039   68              Assess in-hospital death, recurrent myocardial infarction, congestive heart failure, cardiogenic shock                                     According to the physician's decision   CRUSADE database                      Adjusted for baseline patient clinical risk factors, for provider and hospital characteristics

  Puymirat *et al*[@R35]                   France, Retrospective                    2 months            STEMI patients with symptoms\<48 hour                                         · 50% Aspirin\                                                     NR                                  No intervention   2438     63              Assess practices for myocardial infarction management in 'real llife' and with medium and long-term outcomes                               According to the physician's decision   FAST-MI 2010 database                 Adjusted for baseline characteristics of the patients
                                                                                                                                                                                      · 71% Clopidogrel\                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                      · 8% Prasugrel                                                                                                                                                                                                                                                                                                                                                             

  Siller-Matula *et al*[@R39]              Austria, prospective                     2                   STEMI patients treated with in-hospital loading dose of prasugrel             Aspirin and prasugrel                                              5--15 mg IV single dose             No intervention   32       60 (11)         Assess if abciximab is a bridging therapy to achieve adequate levels of platelet inhibition                                                NR                                      Multiplate                            NR

  Silvain *et al*[@R10] (ATLANTIC study)   International, posthoc analysis of RCT   14 hours            STEMI                                                                         Aspirin and ticagrelor                                             NR                                  No intervention   37       56.2 (10.2)     Assess coronary reperfusion prior to percutaneous coronary interven- tion with prehospital or in-hospital ticagrelor 180 mg loading dose   NR                                      VerifyNow assay                       NR
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AMI, acute myocardial infarction; DAPT, dual antiplatelet therapy; IV, intravenous; MACE, major adverse cardiovascular events; NR, not reported; NSTE-ACS, non-ST elevation acute coronary syndrome; NSTEMI, non-ST elevation myocardial infarction; PPCI, primary percutaneous coronary intervention; RCT, randomised controlled trial; STEMI, ST elevation myocardial infarction; VASP, vasodilator-stimulated phosphoprotein.

Morphine administration was variable across the included studies, with six of the observational studies[@R10] not reporting information regarding dose and number or mode of administration. Among RCTs, morphine administration was intravenous or intramuscular at a dose between 2 and 10 mg, either in single or multiple administrations. The forms of antiplatelet therapy used across studies were varied, and firm conclusions cannot be made.

Risk of bias {#s3b}
------------

We judged two of the five RCTs to be at a high overall risk of bias, one[@R31] due to having unclear risk of bias in all but one domain, and the other[@R29] due to a high risk of performance and attrition bias. All observational studies were at risk of bias due to confounding, and all but one[@R36] were at moderate risk of selection of study results. Grendahl and Hansteen[@R38] was additionally at moderate risk of bias due to measurement of outcome. Overall, two observational studies were at critical risk of bias,[@R34] seven were at serious risk of bias[@R36] and three were at a moderate risk of bias[@R10] (online [supplementary material](#SP1){ref-type="supplementary-material"}).

In-hospital mortality {#s3c}
---------------------

Four RCTs (n=2237) and seven observational studies (n=63 112) contributed with data for this outcome. Adjusted pooled results showed an increased risk of in-hospital mortality in the morphine group (RR 1.45; 95% CI 1.10 to 1.91; I^2^=0%; [figure 2](#F2){ref-type="fig"}). Subgroup analysis based on study design (p=0.67 for interaction; [figure 2](#F2){ref-type="fig"}) and ACS subtype (STEMI RR 1.05; 95% CI 0.57 to 1.94; I^2^=0%; NSTE-ACS RR 1.57; 95% CI 1.15 to 2.14; I^2^=0% and p=0.25 for interaction) were both non-significant. Sensitivity analysis by excluding studies at critical risk of bias showed no differences between morphine and control (RR 1.41; 95% CI 0.87 to 2.27; I^2^=0%; n=5872 participants). The GRADE confidence in this estimate is low.

![Forest plot of in-hospital mortality according to morphine use, subgroups according to study design. IV, inverse variance; NSTE-ACS, non-ST elevated acute coronary syndrome; RCT, randomised controlled trials; STEMI, ST-elevated myocardial infarction.](bmjopen-2018-025232f02){#F2}

MACE {#s3d}
----

Three RCTs (n=375) and seven observational studies (n=61 054) contributed with data for this outcome. Adjusted pooled results showed an increased risk of MACE in the morphine group (RR 1.21, 95% CI 1.02 to 1.45; I^2^=0%; [figure 3](#F3){ref-type="fig"}). Subgroup analysis based on study design (p=0.44 for interaction; [figure 3](#F3){ref-type="fig"}) and ACS subtype (STEMI RR 1.20; 95% CI 0.71 to 2.03; I^2^=0%; NSTE-ACS RR 1.21; 95% CI 1.01 to 1.46; I^2^=0% and p=0.98 for interaction) were both non-significant. Sensitivity analysis by excluding studies at critical risk of bias showed no differences between morphine and control (RR 1.40, 95% CI 0.85 to 2.30; I^2^=0%; n=1952). The GRADE confidence in this estimate is low.

![Forest plot of MACE (major adverse cardiovascular events) according to morphine use, subgroups according to study design. IV, inverse variance; RCTs, randomised controlled trails.](bmjopen-2018-025232f03){#F3}

Bleeding {#s3e}
--------

One RCT (n=70) and two observational studies (n=482) contributed with data for major bleeding, while three RCTs (n=375) and three observational studies (n=57 647) contributed with data for minor bleeding. No differences were found between morphine and control in the risk of either major (RR 0.62, 95% CI 0.18 to 2.12; I^2^=0%) or minor (RR 0.62, 95% CI 0.18 to 2.12; I^2^=40%) bleeding (online [supplementary material](#SP1){ref-type="supplementary-material"}). Subgroup analysis based on study design and ACS subtype were both non-significant (major bleeding: p=0.85 and p=0.85 for interaction, respectively; minor bleeding: p=0.20 and p=0.20 for interaction, respectively). The GRADE confidence in these estimates is low for major bleeding and very low for minor bleeding.

Platelet reactivity {#s3f}
-------------------

We present data from 1 and 2 hours after morphine administration, as these are likely to be the most clinically meaningful timepoints. Two RCT (n=82) and two observational studies (n=228) contributed with data for this outcome. One hour after administration, morphine was associated with increased platelet reactivity, with an MD of 59.37 platelet reactivity units (PRU) (95% CI 36.04 to 82.71; I^2^=23%; [figure 4](#F4){ref-type="fig"}). Two hours after administration, morphine remained associated with increased platelet reactivity (MD 68.28 PRU, 95% CI 37.01 to 99.55; I^2^=28%; [figure 5](#F5){ref-type="fig"}). Subgroup analysis based on study design and ACS subtype were both non-significant at both timepoints (p=0.25 for interaction for both timepoints; p=0.24 for interaction for both timepoints, respectively). The GRADE confidence is high for this outcome at both timepoints.

![Forest plot of platelet reactivity at 1 hour postmorphine administration, using the VerifyNow method, subgroups according to study design. IV, inverse variance; RCTs, randomised controlled trails.](bmjopen-2018-025232f04){#F4}

![Forest plot of platelet reactivity at 2 hours postmorphine administration, using the VerifyNow method, subgroups according to study design. IV, inverse variance; RCTs, randomised controlled trails.](bmjopen-2018-025232f05){#F5}

We additionally pooled results using the three trials that reported results using the MEA method.[@R30] These results were consistent with those using the VerifyNow method at both 1 hour (MD 27.80, 95% CI 16.03 to 39.57, I^2^=24%) and 2 hours after morphine administration (MD 19.99, 95% CI 1.52 to 38.46, I^2^=82%).

Additional outcomes {#s3g}
-------------------

We found no differences associated with morphine use, namely regarding the risk of cardiogenic shock (RR 1.48; 95% CI 1.00 to 2.18; I^2^=0%), heart failure (RR 1.17; 95% CI 0.91 to 1.51; I^2^=33%), hypotension (RR 0.93; 95% CI 0.49 to 1.74; I^2^=5%), nausea/emesis (RR 1.84; 95% CI 0.80 to 4.23; I^2^=44%), respiratory insufficiency (RR 0.77; 95% CI 0.31 to 1.91; I^2^=0%) or stent thrombosis (RR 1.13; 95% CI 0.67 to 1.92; I^2^=0%) (online [supplementary material](#SP1){ref-type="supplementary-material"}).

Discussion {#s4}
==========

Our main findings were as follows: (1) morphine was associated with an increased risk of in-hospital mortality and MACE; however, high risk of bias led to low confidence in the results; (2) morphine decreased the antiplatelet effect of P2Y12 inhibitors in the first hours of ACS, and the risk of bias associated with this objective measure was considered to be low.

Despite the widespread use of morphine in chest pain and anxiety relief in patients with ACS, conflicting data about its clinical impact has recently come to light.[@R30] The activation of opioid receptors in the myenteric plexus decreases gut motility and secretion, inhibiting the activation of drugs whose action is directed at the P2Y12 protein and decreasing its absorption and bioavailability. Moreover, morphine is also known for its proemetic and antiperistaltic effects, which can further contribute to the decreased absorption of antiplatelet drugs.

This systematic review was planned and designed to evaluate the safety outcomes associated with morphine use in ACS. Pooled data RCTs and observational studies showed that treatment with morphine in patients with ACS is associated with a significant increase risk of in-hospital mortality, MACE and platelet reactivity.

We found that morphine decreased the antiplatelet effect of P2Y12 inhibitors in the first hours of ACS. The clinical significance of this increase is uncertain, as the magnitude of this change is less than the difference between ticagrelor and clopidogrel in ACS,[@R46] but appears to be at least twice as large as the impact of esomeprazole on the pharmacodynamics of clopidogrel.[@R47] This effect of morphine ceases to be relevant at around the 8 hour mark.[@R36] This may contribute to a delay in the onset of acute medical treatment, a greater prothrombotic milieu and more myocardial damage in patients with ACS. What is more, the analgesic effect of morphine followed by a decreased sympathetic response of the patient, without directly reversing the cause of ACS, may lead physicians to underestimate the severity of the underlying disease and to postpone the referral to an invasive revascularisation procedure. All the above-mentioned reasons may contribute towards the increased risk of in-hospital mortality and MACE related to the use of morphine. In clinical practice, other opioid analgesic drug such as fentanyl can be used, and a recent trial showed that fentanyl treatment in ACS increased platelet reactivity compared with no treatment. Although this suggests a possible class-effect of opioids on antiplatelet drugs, the evidence is sparse and requires further investigation before firm conclusions can be made.[@R48]

Unexpectedly, we did not find an increased risk of nausea/emesis associated with morphine. This raises the likelihood that the reduction of gut secretion and motility is the core effect through which morphine decreases the activation of P2Y12 drugs.

With regard to platelet reactivity, we believe that the magnitude of the difference found supports a change in clinical practice, moving away from a recommendation to use morphine in ACS to recommending not using it routinely. The strength of this recommendation may be controversial due to the nature of the trials used and the other outcomes in this review not being statistically significant.

An important concern when combining randomised and observational data is the extent to which the participants and clinical setting are sufficiently similar to justify their pooling. On this account, the results of this review are robust since we found low heterogeneity across the outcomes of interest and the fact that none of the subgroup analyses comparing RCTs versus observational studies were statistically significant. Further proof of the consistency of the results is that no subgroup analysis showed a difference between STEMI and NSTE-ACS. However, due to concerns over risk of bias across studies, we assessed the certainty in the evidence as low, despite there being little concern regarding inconsistency, indirectness or lack of statistical power.

The key limitation of this review comes from the key limitation of most observational research, namely confounding. In a conservative approach, we attempted to minimise the impact of observational studies and their bias in the estimates by applying a correction factor previously used in other meta-analysis.[@R26] Nevertheless, we must recognise that this adjustment is artificial and limits our results. Another limitation regards the possible differences in the doses and route of administration of morphine that were not available in most of the included studies.

Physicians may administer morphine to patients with more severe forms of chest pain, which may correspond to a more severe underlying ACS. This means that the increased risk of negative clinical outcomes could come as a result of patients being given morphine, or, alternatively, from the fact that morphine is usually reserved for the sickest patients. Because the included observational studies were substantially larger than the RCTs, including them in the meta-analysis could increase the risk of producing a biased result with an undue degree of statistical precision. To minimise this risk, we used methods to decrease the weight given to the largest and most biased studies, providing a more conservative estimate based on the available evidence. In doing so, we have produced the first and only systematic review to date that evaluates this highly relevant clinical question.

Conclusions {#s5}
===========

This systematic review raises concern about the use of morphine in patients with ACS and challenge the current clinical recommendations for its use in ACS. Most data come from studies at high risk of bias when evaluating the true effect of morphine in this setting. As such, a low-bias, adequately powered RCT designed to evaluate this question would be of significant scientific and clinical value. However, there is high certainty that morphine decreased the antiplatelet effect of P2Y12 inhibitors in the first hours of ACS.
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